P153 An Italian centre experience with elexacaftor/tezacaftor/ivacaftor therapy in 6 to 11 year olds with cystic fibrosis

Elexacaftor-tezacaftor-ivacaftor (ETI), a triple CFTR modulator combination, has proven to be highly effective in patients with cystic fibrosis (CF) carrying at least one Phe508del mutation. Since October 2022 triple therapy has been approved in Italy for 6 to 11-year-old children with this genotype. We report preliminary data on efficacy and safety of ETI in that patient population after one month of treatment.